Analysis of Epidemiological Characteristics of New Cardiovascular Diseases in Cancer Patients with Cardiovascular Disease

Table 1

Some systemic cancer therapies having cardiovascular negative impacts [22].

Cancer therapies	Cardiovascular effects	Long-term effects	Mechanisms
Anthracyclines	Cardiotoxicity type I irreversible	Present	Losses of myocardium
Cyclophosphamide		Unlikely	Myocarditis
Cisplatin		Unlikely	Unrecognized
Pyrimidine analogues	Myocardial ischemia	Unlikely	Coronary vasospasm
Anti-VEGF therapies		Unlikely	Arterial thrombosis
Arsenic trioxide	Arrhythmia	Absent	HERG K+ blockages
Selected TKIs			HERG K+ blockages
Cisplatin	Thromboembolism	Unlikely	Endothelial damages
Anti-VEGF therapeutics			Endothelial damages
Selected TKIs	Pleural effusion	Unrecognized	Unrecognized
Chosen TKIs	Peripheral arterial occlusive diseases	Unrecognized	Unrecognized
Selected TKIs	Pulmonary hypertension	Unrecognized	Unrecognized
Anti-VEGF therapies	Arterial hypertension	Unrecognized	Multiple processes
Anti-HER2 therapies	Cardiac dysfunctioning	Unlikely, except when integrated with anthracyclines	Mitochondrial dysfunctioning
Anti-VEGF therapeutics	Type II reversible	Unlikely	Mitochondrial dysfunction